Abstract
Background: Tuberculosis is an infection and caused by gentle growing bacteria. The Internet provides opportunities for people with tuberculosis (TB) to connect with one another to address these challenges.
Objective: The aim of this paper is to introduce readers to the platforms on which Tuberculosis participants interact, to discuss reasons for and risks associated with TB-related activity, and to review research related to the potential impact of individual participation on TB outcomes.
Methods: Research and online content related to Tuberculosis online activity is reviewed, however, the difficulty in accurate prescribing and adhering to these protocols and the emergence of M. tuberculosis strains resistant to multiple drugs and drug-drug interactions that interfere with optimal treatment of Tuberculosis and co-infected patients with the different disease has generated a pressing need for improved Tuberculosis therapies.
Results: Together with the ominous global burden of Tuberculosis, those shortcomings of current medication have contributed to a renewed interest in the development of improved drugs and protocols for the medication of Tuberculosis. This article features obstacles related with the enhanced utilization of existing drugs and difficulties related with the advancement of enhanced products, concentrating on perspectives characteristic in Tuberculosis drug clinical improvement. The participation includes peer support, advocacy, self-expression, seeking and sharing TB information, improving approaches to Tuberculosis data management, and humour.
Conclusion: This article highlights hurdles related to the optimised use of existing drugs and challenges related to the development of improved products, focusing on aspects inherent in Tuberculosis drug clinical development. Concluding comments offer processes for more efficient development of Tuberculosis therapies and increase the quality of life.
Keywords: Tuberculosis, co-infection, tuberculosis regimen, Mycobacterium tuberculosis, Purified Protein Derivative (PPD).
Current Drug Delivery
Title:Tuberculosis Treated by Multiple Drugs: An Overview
Volume: 15 Issue: 3
Author(s): Gyanendra Singh, Prashant Kesharwani*Anand Kumar Srivastava*
Affiliation:
- The International Medical University, School of Pharmacy, Department of Pharmaceutical Technology, Jalan Jalil Perkasa 19, 57000 Kuala Lumpur,Malaysia
- Department of Pharmaceutics, Indian Institute of Technology, Banaras Hindu University, (IIT-BHU), UP-221005, Varanasi,India
Keywords: Tuberculosis, co-infection, tuberculosis regimen, Mycobacterium tuberculosis, Purified Protein Derivative (PPD).
Abstract: Background: Tuberculosis is an infection and caused by gentle growing bacteria. The Internet provides opportunities for people with tuberculosis (TB) to connect with one another to address these challenges.
Objective: The aim of this paper is to introduce readers to the platforms on which Tuberculosis participants interact, to discuss reasons for and risks associated with TB-related activity, and to review research related to the potential impact of individual participation on TB outcomes.
Methods: Research and online content related to Tuberculosis online activity is reviewed, however, the difficulty in accurate prescribing and adhering to these protocols and the emergence of M. tuberculosis strains resistant to multiple drugs and drug-drug interactions that interfere with optimal treatment of Tuberculosis and co-infected patients with the different disease has generated a pressing need for improved Tuberculosis therapies.
Results: Together with the ominous global burden of Tuberculosis, those shortcomings of current medication have contributed to a renewed interest in the development of improved drugs and protocols for the medication of Tuberculosis. This article features obstacles related with the enhanced utilization of existing drugs and difficulties related with the advancement of enhanced products, concentrating on perspectives characteristic in Tuberculosis drug clinical improvement. The participation includes peer support, advocacy, self-expression, seeking and sharing TB information, improving approaches to Tuberculosis data management, and humour.
Conclusion: This article highlights hurdles related to the optimised use of existing drugs and challenges related to the development of improved products, focusing on aspects inherent in Tuberculosis drug clinical development. Concluding comments offer processes for more efficient development of Tuberculosis therapies and increase the quality of life.
Export Options
About this article
Cite this article as:
Singh Gyanendra , Kesharwani Prashant *, Srivastava Kumar Anand *, Tuberculosis Treated by Multiple Drugs: An Overview, Current Drug Delivery 2018; 15 (3) . https://dx.doi.org/10.2174/1567201814666171120125916
DOI https://dx.doi.org/10.2174/1567201814666171120125916 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chorismate Synthase: An Attractive Target For Drug Development Against Orphan Diseases
Current Drug Targets Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Recent Achievements in the Synthesis of Oxazoles
Current Organic Chemistry Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry In Search of Drug Targets for Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs
Current Pharmaceutical Design Preparation of Knockout Extract for Determination of Really Active Compound Using MAb
Current Drug Discovery Technologies Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry 4,6-diaryl Pyrimidones as Constrained Chalcone Analogues: Design, Synthesis and Evaluation as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Current Medicinal Chemistry <i>p</i>-Coumaric Acid: A Naturally Occurring Chemical with Potential Therapeutic Applications
Current Organic Chemistry Morpholine Based Diazenyl Chalcones: Synthesis, Antimicrobial Screening and Cytotoxicity Study
Anti-Cancer Agents in Medicinal Chemistry Lessons from Seven Decades of Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry Structure-Based Approaches to the Development of Novel Anti-Malarials
Current Drug Targets Ceric Ammonium Nitrate Catalysed Stereoselective Synthesis of β-Aminoketones Using 3-Aryl-4-Formylsydnones
Letters in Organic Chemistry Advances of Inorganic Materials in the Detection and Therapeutic Uses against Coronaviruses
Current Medicinal Chemistry Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design Microwave-assisted Single Step Cinnamic Acid Derivatization and Evaluation for Cytotoxic Potential
Current Pharmaceutical Biotechnology